Last checked at 27 Jun 2019 10:07
Allergy Therapeutics earnings set to top expectations
(Sharecast News) - Biotechnology group Allergy Therapeutics told investors on Thursday that 2019 full-year earnings looked set to come in ahead of market expectations.
Read more
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Allergy Thera. Share News (AGY)
AGY Share
Price
AGY Share
News
AGY Share
Chat
AGY Share
Trades9
AGY
Live RNS
AGY Share
Charts
AGY Level 2
Console
AGY Live
Share Price
AGY Broker
Ratings
AGY Directors
Deals
AGY Financial
Diary
AGY
Fundamentals
AGY Short
Positions
AGY
Media
Allergy Thera. Information
Share Price Information for Allergy Thera. (AGY)
Share Price is delayed by 15 minutes
Get Live Data
Share Price:
2.85
Bid:
2.80
Ask:
2.90
Change:
0.00 (0.00%)
Spread:
0.10 (3.571%)
Open:
2.85
High:
2.85
Low:
2.85
Prev. Close:
2.85
Last checked at -
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.19 Jun 2019 13:39
Allergy Therapeutics Hires Former Advanced Medical Solutions CFO
(Alliance News) - Allergy Therapeutics PLC on Wednesday said it has appointed Mary Tavener as a non-executive director with immediate effect.The biotechnology company said Tavener has in 19
Read more20 May 2019 13:42
Allergy Therapeutics Vaccine Helps Dust Mite Allergy Symptoms In Study
LONDON (Alliance News) - Allergy Therapeutics PLC on Monday said its Acarovac MPL vaccine improved dust mite allergy symptoms during a phase one study.The AM101 study, which was open-label
Read more20 May 2019 11:00
Allergy Therapeutics flags positive outcomes from recent treatment trial
(Sharecast News) - Biotechnology company Allergy Therapeutics announced positive Phase 1 safety and tolerability results of subcutaneous 'Acarovac MPL' (monophosphoryl lipid A) in patients with house dust mite-induced allergic rhinoconjunctivitis on Monday.
Read more25 Apr 2019 10:01
Allergy Therapeutics eyes 2020 start for hay fever inoculation trials
(Sharecast News) - Commercial biotechnology company Allergy Therapeutics will kick off phase III trials of its short-course inoculation for grass pollen-induced hay fever in the second half of 2020 following a successful round of meetings with German and American regulatory bodies.
Read more18 Mar 2019 10:44
WINNERS & LOSERS SUMMARY: Footasylum Rises On "Generous" JD Offer
LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Monday.----------FTSE 100 - Tinto, up 2.3%, Group, up in
Read more18 Mar 2019 10:06
Allergy Therapeutics Surprised As Vaccine Trial Fails Primary Endpoint
LONDON (Alliance News) - Allergy Therapeutics PLC on Monday said a phase three trial of its birch pollen allergy vaccine did not meet its primary endpoint.Shares in Allergy Therapeutics 43%
Read more18 Mar 2019 08:51
Allergy Therapeutics shares plunge after disappointing clinical trial
(Sharecast News) - Shares in biotechnology company Allergy Therapeutics were plunging on Monday morning, after it announced disappointing top-line results from the phase 3 clinical trial 'B301' of its new adjuvanted birch allergoid product.
Read more6 Mar 2019 11:13
Allergy Therapeutics Interim Profit Rises 67% On Higher Revenue
LONDON (Alliance News) - Allergy Therapeutics PLC on Wednesday reported significantly higher profit for the first six months of its financial year as revenue rose and research costs were the to of
Read more6 Mar 2019 10:19
Allergy Therapeutics profits rise as it spends less on R&D
(Sharecast News) - Specialty pharmaceutical group Allergy Therapeutics announced its unaudited interim results for the six months ended 31 December on Wednesday, reporting a 10.6% improvement in revenue on both a reported and constant currency basis, to £46.7m.
Read more16 Jan 2019 12:26
Allergy Therapeutics First Half Meets Forecasts On European Growth
LONDON (Alliance News) - Allergy immunology vaccines developer Allergy Therapeutics PLC said Wednesday trading in the first half was in line with expectations.Allergy Therapeutics expects -
Read more16 Jan 2019 08:51
Allergy Therapeutics sees good first-half progress
(Sharecast News) - Commercial biotechnology company Allergy Therapeutics updated the market for the six months ended 31 December on Wednesday, reporting that it was trading in line with board expectations.
Read more27 Nov 2018 13:12
Allergy Therapeutics Continues To Perform Well, Revenue Up "Strongly"
LONDON (Alliance News) - Allergy Therapeutics PLC said Tuesday it has continued to perform well, with revenue up "strongly" from the prior year and sales in line with market financial to
Read more27 Nov 2018 10:05
Allergy Therapeutics boosted by strong German performance
(Sharecast News) - Biotechnology company Allergy Therapeutics has seen revenues increase throughout the first half of its trading year thanks to an improved market share for its allergy vaccines on the continent.
Read more23 Oct 2018 16:11
BlackRock Lowers Allergy Therapeutics Stake Below Threshold (ALLISS)
LONDON (Alliance News) - Allergy Therapeutics PLC said Tuesday that BlackRock Inc lowered its stake in the company to below the 5% threshold.Prior to the deal, BlackRock held a 5.1% in the
Read more